Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: The study, the patient, the bug or the drug?

Journal of Infection

Volumn 66, Issue 5, 2013, Pages 401-414

  Vardakas, Konstantinos Z ^a,b   Rafailidis, Petros I ^a,c   Konstantelias, Athanasios A ^a,d   Falagas, Matthew E ^a,b,e  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c HENRY DUNANT HOSPITAL   (Greece)

^d AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acinetobacter; Enterobacter; Enterobacteriacae; Escherichia coli; Klebsiella; Proteus; Pseudomonas; Risk factor; Stenotrophomonas

Indexed keywords

ANTIBIOTIC AGENT; STREPTOMYCIN;

ACINETOBACTER; AGE DISTRIBUTION; APACHE; BACTERIUM ISOLATION; BIBLIOGRAPHIC DATABASE; COMORBIDITY; DISEASE SEVERITY; DRUG INDICATION; ENTEROBACTERIACEAE; GENE MUTATION; GRAM NEGATIVE INFECTION; HUMAN; INTENSIVE CARE UNIT; MALIGNANT NEOPLASTIC DISEASE; MEDLINE; MORTALITY; MULTIDRUG RESISTANCE; OUTCOME ASSESSMENT; PNEUMONIA; PROGNOSIS; PSEUDOMONAS AERUGINOSA; REVIEW; SCOPUS DATABASE; SEPTIC SHOCK; SEX DIFFERENCE; SURVIVAL RATE;

ANTI-BACTERIAL AGENTS; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; RISK FACTORS;

EID: 84875590009     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2012.10.028     Document Type: Review

References (66)

1. Falagas M.E., Bliziotis I.A., Kasiakou S.K., Samonis G., Athanassopoulou P., Michalopoulos A. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis 2005, 5:24.
2. Falagas M.E., Karageorgopoulos D.E. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis 2008 Apr 1, 46(7):1121-1122. author reply 2.
3. Falagas M.E., Rafailidis P.I., Matthaiou D.K., Virtzili S., Nikita D., Michalopoulos A. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents 2008 Nov, 32(5):450-454.
4. Falagas M.E., Koletsi P.K., Bliziotis I.A. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006 Dec, 55(Pt 12):1619-1629.
5. Magiorakos A.P., Srinivasan A., Carey R.B., Carmeli Y., Falagas M.E., Giske C.G., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012 Mar, 18(3):268-281.
6. Cosgrove S.E., Sakoulas G., Perencevich E.N., Schwaber M.J., Karchmer A.W., Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003 Jan 1, 36(1):53-59.
7. Giske C.G., Monnet D.L., Cars O., Carmeli Y. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008 Mar, 52(3):813-821.
8. Schwaber M.J., Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007 Nov, 60(5):913-920.
9. Todeschini G., Franchini M., Tecchio C., Meneghini V., Pizzolo G., Veneri D., et al. Improved prognosis of Pseudomonas aeruginosa bacteremia in 127 consecutive neutropenic patients with hematologic malignancies. Int J Infect Dis 1998 Winter, 3(2):99-104.
10. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000 Apr 19, 283(15):2008-2012.
11. Katsaragakis S., Markogiannakis H., Samara E., Pachylaki N., Theodoraki E.M., Xanthaki A., et al. Predictors of mortality of Acinetobacter baumannii infections: a 2-year prospective study in a Greek surgical intensive care unit. Am J Infect Control 2010 Oct, 38(8):631-635.
12. Kwa A.L., Low J.G., Lee E., Kurup A., Chee H.L., Tam V.H. The impact of multidrug resistance on the outcomes of critically ill patients with Gram-negative bacterial pneumonia. Diagn Microbiol Infect Dis 2007 May, 58(1):99-104.
13. Lin C.C., Liu T.C., Kuo C.F., Liu C.P., Lee C.M. Aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii pneumonia: experience in a tertiary care hospital in northern Taiwan. J Microbiol Immunol Infect 2011 Aug, 43(4):323-331.
14. Michalopoulos A., Falagas M.E., Karatza D.C., Alexandropoulou P., Papadakis E., Gregorakos L., et al. Epidemiologic, clinical characteristics, and risk factors for adverse outcome in multiresistant gram-negative primary bacteremia of critically ill patients. Am J Infect Control 2011 Jun, 39(5):396-400.
15. Pinheiro M.R., Lacerda H.R., Melo R.G., Maciel M.A. Pseudomonas aeruginosa infections: factors relating to mortality with emphasis on resistance pattern and antimicrobial treatment. Braz J Infect Dis 2008 Dec, 12(6):509-515.
16. Anderson D.J., Engemann J.J., Harrell L.J., Carmeli Y., Reller L.B., Kaye K.S. Predictors of mortality in patients with bloodstream infection due to ceftazidime-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 2006 May, 50(5):1715-1720.
17. Anunnatsiri S., Tonsawan P. Risk factors and clinical outcomes of multidrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Thailand. Southeast Asian J Trop Med Public Health 2011 May, 42(3):693-703.
18. Jamulitrat S., Arunpan P., Phainuphong P. Attributable mortality of imipenem-resistant nosocomial Acinetobacter baumannii bloodstream infection. J Med Assoc Thai 2009 Mar, 92(3):413-419.
19. Peralta G., Sanchez M.B., Garrido J.C., De Benito I., Cano M.E., Martinez-Martinez L., et al. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. J Antimicrob Chemother 2007 Oct, 60(4):855-863.
20. Hirsch E.B., Cottreau J.M., Chang K.T., Caeiro J.P., Johnson M.L., Tam V.H. A model to predict mortality following Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis 2012 Jan, 72(1):97-102.
21. Johnson L.E., D'Agata E.M., Paterson D.L., Clarke L., Qureshi Z.A., Potoski B.A., et al. Pseudomonas aeruginosa bacteremia over a 10-year period: multidrug resistance and outcomes in transplant recipients. Transpl Infect Dis 2009 Jun, 11(3):227-234.
22. Kuo L.C., Lai C.C., Liao C.H., Hsu C.K., Chang Y.L., Chang C.Y., et al. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome. Clin Microbiol Infect 2007 Feb, 13(2):196-198.
23. Kwon K.T., Oh W.S., Song J.H., Chang H.H., Jung S.I., Kim S.W., et al. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother 2007 Mar, 59(3):525-530.
24. Lee Y.C., Huang Y.T., Tan C.K., Kuo Y.W., Liao C.H., Lee P.I., et al. Acinetobacter baumannii and Acinetobacter genospecies 13TU and 3 bacteraemia: comparison of clinical features, prognostic factors and outcomes. J Antimicrob Chemother 2011 Aug, 66(8):1839-1846.
25. Lim S.K., Lee S.O., Choi S.H., Choi J.P., Kim S.H., Jeong J.Y., et al. The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections. J Korean Med Sci 2011 Mar, 26(3):325-331.
26. Lye D.C., Earnest A., Ling M.L., Lee T.E., Yong H.C., Fisher D.A., et al. The impact of multidrug resistance in healthcare-associated and nosocomial Gram-negative bacteraemia on mortality and length of stay: cohort study. Clin Microbiol Infect 2011 May, 18(5):502-508.
27. Suarez C., Pena C., Tubau F., Gavalda L., Manzur A., Dominguez M.A., et al. Clinical impact of imipenem-resistant Pseudomonas aeruginosa bloodstream infections. J Infect 2009 Apr, 58(4):285-290.
28. Tam V.H., Rogers C.A., Chang K.T., Weston J.S., Caeiro J.P., Garey K.W. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother 2010 Sep, 54(9):3717-3722.
29. Ye J.J., Lin H.S., Kuo A.J., Leu H.S., Chiang P.C., Huang C.T., et al. The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii. J Infect 2011 Nov, 63(5):351-361.
30. Ye Y., Li J.B., Ye D.Q., Jiang Z.J. Enterobacter bacteremia: clinical features, risk factors for multiresistance and mortality in a Chinese University Hospital. Infection 2006 Oct, 34(5):252-257.
31. Metan G., Sariguzel F., Sumerkan B. Factors influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia. Eur J Intern Med 2009 Sep, 20(5):540-544.
32. Trecarichi E.M., Tumbarello M., Caira M., Candoni A., Cattaneo C., Pastore D., et al. Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies. Haematologica 2011 Jan, 96(1):e1-3. author reply e4.
33. Tumbarello M., Repetto E., Trecarichi E.M., Bernardini C., De Pascale G., Parisini A., et al. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality. Epidemiol Infect 2011 Nov, 139(11):1740-1749.
34. Cao B., Wang H., Sun H., Zhu Y., Chen M. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J Hosp Infect 2004 Jun, 57(2):112-118.
35. Gudiol C., Tubau F., Calatayud L., Garcia-Vidal C., Cisnal M., Sanchez-Ortega I., et al. Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother 2011 Mar, 66(3):657-663.
36. Liao C.H., Sheng W.H., Chen Y.C., Hung C.C., Wang J.T., Chang S.C. Predictive value of the serum bactericidal test for mortality in patients infected with multidrug-resistant Acinetobacter baumannii. J Infect 2007 Aug, 55(2):149-157.
37. Munoz-Price L.S., Zembower T., Penugonda S., Schreckenberger P., Lavin M.A., Welbel S., et al. Clinical outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections: study of a 2-state monoclonal outbreak. Infect Control Hosp Epidemiol 2010 Oct, 31(10):1057-1062.
38. Lee N.Y., Chang T.C., Wu C.J., Chang C.M., Lee H.C., Chen P.L., et al. Clinical manifestations, antimicrobial therapy, and prognostic factors of monomicrobial Acinetobacter baumannii complex bacteremia. J Infect 2010 Sep, 61(3):219-227.
39. Lee N.Y., Lee H.C., Ko N.Y., Chang C.M., Shih H.I., Wu C.J., et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 2007 Jun, 28(6):713-719.
40. Joung M.K., Kwon K.T., Kang C.I., Cheong H.S., Rhee J.Y., Jung D.S., et al. Impact of inappropriate antimicrobial therapy on outcome in patients with hospital-acquired pneumonia caused by Acinetobacter baumannii. J Infect 2010 Sep, 61(3):212-218.
41. Rothman K.J., Greenland S. Causation and causal inference in epidemiology. Am J Public Health 2005, 95(Suppl. 1):S144-S150.
42. McGregor J.C., Rich S.E., Harris A.D., Perencevich E.N., Osih R., Lodise T.P., et al. A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. Clin Infect Dis 2007 Aug 1, 45(3):329-337.
43. Falagas M.E., Kopterides P. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect 2006 Sep, 64(1):7-15.
44. Harbarth S., Nobre V., Pittet D. Does antibiotic selection impact patient outcome?. Clin Infect Dis 2007 Jan 1, 44(1):87-93.
45. Bjorkholm B., Sjolund M., Falk P.G., Berg O.G., Engstrand L., Andersson D.I. Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori. Proc Natl Acad Sci U S A 2001 Dec 4, 98(25):14607-14612.
46. Bjorkman J., Hughes D., Andersson D.I. Virulence of antibiotic-resistant Salmonella typhimurium. Proc Natl Acad Sci U S A 1998 Mar 31, 95(7):3949-3953.
47. Bjorkman J., Nagaev I., Berg O.G., Hughes D., Andersson D.I. Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 2000 Feb 25, 287(5457):1479-1482.
48. Bouma J.E., Lenski R.E. Evolution of a bacteria/plasmid association. Nature 1988 Sep 22, 335(6188):351-352.
49. Schrag S.J., Perrot V., Levin B.R. Adaptation to the fitness costs of antibiotic resistance in Escherichia coli. Proc Biol Sci 1997 Sep 22, 264(1386):1287-1291.
50. Bristianou M., Panagou C., Adamis T., Raftogiannis M., Antonopoulou A., Chrisofos M., et al. The impact of multidrug resistance on the pathogenicity of Escherichia coli: an experimental study. Int J Antimicrob Agents 2008 Mar, 31(3):216-223.
51. Giamarellos-Bourboulis E.J., Koussoulas V., Panagou C., Adamis T., Baziaka F., Skiadas I., et al. Experimental sepsis using Pseudomonas aeruginosa: the significance of multi-drug resistance. Int J Antimicrob Agents 2004 Oct, 24(4):357-361.
52. Zhou Z., Ren J., Liu H., Gu G., Li J. Pandrug-resistant isolate of Klebsiella pneumoniae causes less damage than drug-susceptible isolates in a rabbit model. Clin Invest Med 2011, 34(1):E38-E44.
53. Giamarellos-Bourboulis E.J., Plachouras D., Tzivra A., Kousoulas V., Bolanos N., Raftogiannis M., et al. Stimulation of innate immunity by susceptible and multidrug-resistant Pseudomonas aeruginosa: an in vitro and in vivo study. Clin Exp Immunol 2004 Feb, 135(2):240-246.
54. Linares J.F., Lopez J.A., Camafeita E., Albar J.P., Rojo F., Martinez J.L. Overexpression of the multidrug efflux pumps MexCD-OprJ and MexEF-OprN is associated with a reduction of type III secretion in Pseudomonas aeruginosa. J Bacteriol 2005 Feb, 187(4):1384-1391.
55. Sanchez P., Linares J.F., Ruiz-Diez B., Campanario E., Navas A., Baquero F., et al. Fitness of in vitro selected Pseudomonas aeruginosa nalB and nfxB multidrug resistant mutants. J Antimicrob Chemother 2002 Nov, 50(5):657-664.
56. Iregui M., Ward S., Sherman G., Fraser V.J., Kollef M.H. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002 Jul, 122(1):262-268.
57. Larche J., Azoulay E., Fieux F., Mesnard L., Moreau D., Thiery G., et al. Improved survival of critically ill cancer patients with septic shock. Intensive Care Med 2003 Oct, 29(10):1688-1695.
58. Davey P.G., Marwick C. Appropriate vs. inappropriate antimicrobial therapy. Clin Microbiol Infect 2008 Apr, 14(Suppl. 3):15-21.
59. Bhat S.V., Peleg A.Y., Lodise T.P., Shutt K.A., Capitano B., Potoski B.A., et al. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. Antimicrob Agents Chemother 2007 Dec, 51(12):4390-4395.
60. Defife R., Scheetz M.H., Feinglass J.M., Postelnick M.J., Scarsi K.K. Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin. Antimicrob Agents Chemother 2009 Mar, 53(3):1074-1079.
61. Falagas M.E., Tansarli G.S., Rafailidis P.I., Kapaskelis A., Vardakas K.Z. Impact of antibiotic minimum inhibitory concentration on infection outcome in patients with susceptible Gram negative bacteria: a systematic review and meta-analysis. Antimicrob Agents Chemother 2012, 56(8):4214-4222.
62. Tam V.H., Gamez E.A., Weston J.S., Gerard L.N., Larocco M.T., Caeiro J.P., et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis 2008 Mar 15, 46(6):862-867.
63. Clinical and Laboratory Standards Institute Performance standards for antimicrobial testing: twenty-first informational supplement 2011, CLSI document M100-S21, Wayne PCaLSI.
64. European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters 2012, [cited; 2:Available from].
65. Falagas M.E., Karageorgopoulos D.E. Extended-spectrum beta-lactamase-producing organisms. J Hosp Infect 2009 Dec, 73(4):345-354.
66. Paterson D.L., Bonomo R.A. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005 Oct, 18(4):657-686.